Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Patrick Pauwels (Belgium), Nicolas Girard (France), Luis Paz-Ares (Spain). Session 2: From molecular target to molecular resistance in NSCLC - Panel discussion. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Member's Comments

No comment yet.

Related content which might interest you: Session 3: From molecular addiction to therapeutic strategy in NSCLC - Panel discussion Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Session 1: From molecular alterations to cancer immunity in NSCLC - Panel discussion Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Session 5: From PD1/PD-L1 monotherapy in selected patients to PD1/PD-L1 combo for all NSCLC - Panel discussion Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Panel discussion: Improving the pathway of lung cancer patients, can we do it better? Source: ERS webinar 2021: Panel discussion on improving the pathway of lung cancer patients, can we do it better? Year: 2021 Integration of molecular testing in the classification of NSCLC: the French experience Source: International Congress 2014 – The more in-depth classification of lung cancer: relevance for patients and science Year: 2014 Session 1: The meaning of the words - General discussion Source: Research Seminar 2021 – Lung function trajectories from birth to death, health and disease, and pre-war to today Year: 2021 Early-Career delegates session - Panel discussion Source: ERS Lung Science Conference 2021 Year: 2021 LSC - 2020 - Comprehensive characterization of the immune landscape within different molecular subtypes of small cell lung cancer (SCLC) Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020 General discussion: Day 2 Source: Course 2015 - Clinical exercise testing Year: 2015 General discussion: Day 1 Source: Course 2015 - Clinical exercise testing Year: 2015 Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015